logo-loader

Matinas BioPharma brings in $50M to fund drug development

Published: 12:06 14 Jan 2020 EST

$100 bills
The biopharmaceutical company offered more than 32.2 million shares at $1.55 each

Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) has closed a registered public offering of its stock, raising around $50 million gross. 

The biopharmaceutical company offered more than 32.2 million shares at a price of $1.55 per share. The underwriters of the deal have been granted a 30-day option to purchase up to an additional 4.8 million shares.

READ: Matinas BioPharma evaluates formulating compounds using its LNC technology with Roche’s Genentech

Matinas plans to use the proceeds to further develop MAT9001, its prescription-only omega 3 fatty acid, and other product candidates.

The sole lead active bookrunner for the offering was Piper Sandler & Co.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com 

Follow him on Twitter @andrew_kessel

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

1 hour, 30 minutes ago